Skip to main content
. Author manuscript; available in PMC: 2016 Aug 11.
Published in final edited form as: Urol Oncol. 2014 Oct 7;33(2):70.e15–70.e22. doi: 10.1016/j.urolonc.2014.07.005

Table 1.

Pre- and post- treatment characteristics and pathologic outcomes of NCCN low–& intermediate- risk men undergoing radical prostatectomy at University of Pennsylvania, 1990–2012 (Overall Cohort).

Caucasian Cohort n=1031 % African-American Cohort n=234 % p-Value
Age, Y 0.48
Median 60 58
mean 59.1 57.8
IQR 54–64 52–62

iPSA ng/ml 0.89
0–4.0 271 26 59 25
4.01 - 10 659 64 150 65
10.01- 20 101 10 25 11
median 5.1 5.6
mean 5.8 6.2
IQR 4.1 -- 6.7 4.1 -- 7.8

Biopsy Gleason <0.001*
≤6 948 90 162 67
7(3+4) 103 10 54 23

Clinical Stage 0.63*
T1A-C 583 81 149 85
T2A 111 16 22 12
T2B 8 1 4 2
T2C 12 2 1 1
Year of prostatectomy 0.006
median 2003 2004
mean 2002.7 2003.7
IQR 1999–2007 2000–2008

Pathologic Stage 0.07*
pT2N0 802 77 175 74
pT3aN0 202 20 44 19
pT3bN0 23 2 13 6
pT4aN0 4 1 2 1

Pathologic Gleason <0.001*
≤6 596 57 113 46
7(3+4) 229 22 81 36
7(4+3) 35 4 14 7
7(unspecified) 145 14 22 9
8 to 10 26 3 4 2

Gleason upgrading 0.25*
6/7 to 7/(8–10) 369 35 72 30

Adverse pathologic features 0.35*
0 757 73 164 69
1 147 15 33 15
≥2 127 12 37 16

Extraprostatic spread 223 22 58 25 0.32*

Seminal Vesicle invasion 27 3 13 6 0.02*

Positive surgical margin 162 16 39 17 0.71*

Radiotherapy 11 1 3 1 0.78*

ADT 35 3 8 3 0.5*

NOTE. Boldfaced values represent statistically signi cant differences between groups.

Abbreviations: iPSA- initial Prostate-specific antigen, IQR- interquartile range;

NCCN- National Comprehensive Cancer Network; ADT- Androgen depravation therapy

*

P value derived from Person’s chi-square test.

P value derived from analysis of variance model.

Adverse pathologic features: extraprostatic extension, seminal vesicle invasion, and/or positive surgical margin.